Jun 19, 2020

Novartis pilots new methods of accessing healthcare professionals with Highp

Company aims to improve communication with healthcare professionals beyond standard email to stand out from the competitors.

article header

Novartis headquater in Basel

Warsaw, Poland - Jun 18, 2020 - Connectmedica today announced that Novartis, one of the largest international pharmaceutical company, based in Switzerland, selected the Highp platform to deliver best in class access to health care professionals across multiple regions, including APAC, MENA, and EMEA.

“We are excited to work with an amazing team from Novartis to deliver best in class customer experience to healthcare professionals across so many markets, “ said Igor Gnot, chief executive officer of Connectmedica” -. Our goal is to pilot our complete operational model that comes hand in hand with innovative Highp technology; as a result, bringing outstanding results for Novartis. “

“Connectmedica is committed to moving the customer experience forward with a brand new approach to service delivery across the globe, “ said Michael Komorniczak, Strategy Business Director at Connectmedica. “ We believe this is an excellent opportunity for pharmaceutical companies to get quickly beyond competitors with best in class approach to communication. We are proud to start working with Novartis in support of their vital mission to offer high-quality sales teams and services. “
 

Additional information

For more on Highp,
visit: gethighp.com

Connect with Highp on Linkedin:
https://pl.linkedin.com/showcase/highp

Follow us on Twitter:
https://twitter.com/connectmedica

 

About Highp and Connectmedica

Highp is Connectmedica’s brand of innovative technology bringing new quality to professional communication with healthcare professionals. Highp is Connectmedica essential product with end-to-end support across 40+ markets worldwide. We are committed to innovation, product excellence, and customer success. 

Connectmedica is headquartered in Warsaw, Poland, founded by Igor Gnot and investors from the USA.

For more information, visit connectmedica.com